Contact
searchSearch
HMP Global

Rheumatology Topic Center

Featured Article

News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care
News
Room for Improvement in Polymyalgia Rheumatica Referral, Management
01/26/2023
Jolynn Tumolo
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people...
01/26/2023
First Report Managed Care
News
Treatment Reduces Disease Activity in Patients With Steroid-Refractory Polymyalgia Rheumatica
01/20/2023
Maria Asimopoulos
For patients with relapsing polymalgia rheumatica, an anti-IL-6Rα monoclonal antibody demonstrated significant efficacy vs placebo, according to recent findings.
For patients with relapsing polymalgia rheumatica, an anti-IL-6Rα monoclonal antibody demonstrated significant efficacy vs placebo, according to recent findings.
For patients with relapsing...
01/20/2023
First Report Managed Care
News
IL-17A Inhibition With Treatment Improves Symptoms of Psoriatic Arthritis
10/27/2022
Edan Stanley
Utilizing Power Doppler ultrasound, researchers examined the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active psoriatic arthritis.
Utilizing Power Doppler ultrasound, researchers examined the dynamics of response of synovitis to IL-17A inhibition with secukinumab in patients with active psoriatic arthritis.
Utilizing Power Doppler...
10/27/2022
First Report Managed Care

Newsfeed

News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care
News
Task Force Publishes Target-To-Treat Guidance for GCA and PMR
03/12/2024
Jolynn Tumolo
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force recently published the first target-to-treat (T2T) recommendations for patients with giant cell arteritis (GCA) and polymyalgia rheumatica (PMR) in the Annals of the Rheumatic Diseases.
An international task force...
03/12/2024
First Report Managed Care
News
Therapy Reduces Disease Activity in Patients With Polymyalgia Rheumatica
02/15/2023
Hannah Musick
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced disease activity in patients with polymyalgia rheumatica, but researchers say more evidence is needed to clarify the agent's potential benefits and harm.
A monoclonal antibody reduced...
02/15/2023
First Report Managed Care
News
Adalimumab vs Etanercept for Rheumatoid Arthritis: Comparing Adverse Reactions, Drug Survival
02/03/2023
Jolynn Tumolo
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the frequency of adverse drug reactions, incidence of treatment discontinuation, and other drug-related outcomes in patients with rheumatoid arthritis treated with adalimumab or etanercept.
Researchers evaluated the...
02/03/2023
First Report Managed Care
News
Room for Improvement in Polymyalgia Rheumatica Referral, Management
01/26/2023
Jolynn Tumolo
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people with polymyalgia rheumatica are not referred for diagnosis," according to findings from a new survey.
“A large proportion of people...
01/26/2023
First Report Managed Care
News
Treatment Reduces Disease Activity in Patients With Steroid-Refractory Polymyalgia Rheumatica
01/20/2023
Maria Asimopoulos
For patients with relapsing polymalgia rheumatica, an anti-IL-6Rα monoclonal antibody demonstrated significant efficacy vs placebo, according to recent findings.
For patients with relapsing polymalgia rheumatica, an anti-IL-6Rα monoclonal antibody demonstrated significant efficacy vs placebo, according to recent findings.
For patients with relapsing...
01/20/2023
First Report Managed Care
News
Balancing Clinical Outcomes and Cost: The Value of Biosimilars in Retinal Disease Management
09/26/2025
Juliet Gallagher
A recent study examining the impact of retinal diseases highlights their significant clinical, social, and economic burden.
A recent study examining the impact of retinal diseases highlights their significant clinical, social, and economic burden.
A recent study examining the...
09/26/2025
First Report Managed Care
News
Trump Administration to Test AI-Powered Prior Authorization in Medicare
09/25/2025
Grace Taylor, MS, MA
The Trump administration is set to launch a decade-long Medicare pilot that uses artificial intelligence (AI)-driven prior authorization to curb costs, sparking bipartisan concern over access to care and patient safety.
The Trump administration is set to launch a decade-long Medicare pilot that uses artificial intelligence (AI)-driven prior authorization to curb costs, sparking bipartisan concern over access to care and patient safety.
The Trump administration is set...
09/25/2025
First Report Managed Care
News
Policy Impact: FDA’s Interchangeability Designation Expands Biosimilar Access
09/25/2025
Juliet Gallagher
Insulin glargine, marketed as Semglee and its biosimilar insulin glargine-yfgn, was granted interchangeable status, allowing pharmacists to substitute it for the branded originator without requiring prescriber intervention. A new economic...
Insulin glargine, marketed as Semglee and its biosimilar insulin glargine-yfgn, was granted interchangeable status, allowing pharmacists to substitute it for the branded originator without requiring prescriber intervention. A new economic...
Insulin glargine, marketed as...
09/25/2025
First Report Managed Care
News
How Timing Shapes Biosimilar Success: Insights from US Market Data
09/24/2025
Juliet Gallagher
A recent study published in Value in Health sheds light on the competitive dynamics of biosimilar drugs in the US, specifically examining whether first-mover advantages resemble those seen in generic drug markets.
A recent study published in Value in Health sheds light on the competitive dynamics of biosimilar drugs in the US, specifically examining whether first-mover advantages resemble those seen in generic drug markets.
A recent study published in...
09/24/2025
First Report Managed Care
Hero Image
News
‘First Report Managed Care’ Webinar to Address Specialty Pharmacy Disruption, Cost Pressures, and Patient Access
09/24/2025
Danielle Sposato
Rising specialty drug costs, surging demand for GLP-1 therapies, and ongoing supply chain and policy challenges are putting patient access at risk. To address these pressures, First Report Managed Care will host a complimentary 60-minute...
Rising specialty drug costs, surging demand for GLP-1 therapies, and ongoing supply chain and policy challenges are putting patient access at risk. To address these pressures, First Report Managed Care will host a complimentary 60-minute...
Rising specialty drug costs,...
09/24/2025
First Report Managed Care
News
Biosimilars Match Humira in Structure, Show Greater Stability Under Real-World Stress
09/22/2025
Juliet Gallagher
A new analytical study underscores how advanced nuclear magnetic resonance (NMR) spectroscopy can sharpen head-to-head comparisons between Humira (adalimumab) and its biosimilars—particularly when products are challenged under real-world...
A new analytical study underscores how advanced nuclear magnetic resonance (NMR) spectroscopy can sharpen head-to-head comparisons between Humira (adalimumab) and its biosimilars—particularly when products are challenged under real-world...
A new analytical study...
09/22/2025
First Report Managed Care
News
$3.2 Million Saved Through Biosimilar Substitution in Rheumatology Clinics
09/19/2025
Juliet Gallagher
A study published in the Journal of Clinical Rheumatology found that a recent initiative at a large academic medical center significantly increased biosimilar uptake and generated substantial cost savings through targeted interventions.
A study published in the Journal of Clinical Rheumatology found that a recent initiative at a large academic medical center significantly increased biosimilar uptake and generated substantial cost savings through targeted interventions.
A study published in the Journal...
09/19/2025
First Report Managed Care
News
Pharmacists Lead, Physicians Lag? Provider Perspectives on Biosimilars and Interchangeability
09/18/2025
Juliet Gallagher
A new cross-sectional survey of 249 US outpatient clinicians—150 physicians and 99 pharmacists who treat immunologic conditions—offers a timely snapshot of how front-line decision-makers view biosimilars and the US Food and Drug...
A new cross-sectional survey of 249 US outpatient clinicians—150 physicians and 99 pharmacists who treat immunologic conditions—offers a timely snapshot of how front-line decision-makers view biosimilars and the US Food and Drug...
A new cross-sectional survey of...
09/18/2025
First Report Managed Care
News
Payer-Driven Biosimilar Preferences Create Financial and Operational Strain for Health Systems
09/17/2025
Juliet Gallagher
The expansion of US Food and Drug Administration (FDA)-approved biosimilars has been heralded as a major advancement for lowering healthcare costs in the US, with the potential to reduce both system-wide expenditures and patient out-of-pocket...
The expansion of US Food and Drug Administration (FDA)-approved biosimilars has been heralded as a major advancement for lowering healthcare costs in the US, with the potential to reduce both system-wide expenditures and patient out-of-pocket...
The expansion of US Food and...
09/17/2025
First Report Managed Care
News
DTX101 Gene Therapy Ends Development, Offers Key Lessons for Future Hemophilia B Treatment Strategies
09/16/2025
Grace Taylor, MS, MA
Early-phase trials of the DTX101 gene therapy in hemophilia B showed manageable safety but insufficient efficacy, leading to program discontinuation while offering critical insights for future gene therapy development.
Early-phase trials of the DTX101 gene therapy in hemophilia B showed manageable safety but insufficient efficacy, leading to program discontinuation while offering critical insights for future gene therapy development.
Early-phase trials of the DTX101...
09/16/2025
First Report Managed Care

Insights

Interview
Lower Costs, Improved Outcomes for Patients Achieving Early RA Remission
07/23/2019
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD, assistant professor at the University of Twente in Enschede in the Netherlands, discusses why achieving early remission for patients with rheumatoid arthritis is important to payers and how it can result in...
Peter M ten Klooster, PhD,...
07/23/2019
First Report Managed Care
Interview
Impact of Artificial Intelligence on Patient Outcomes, Cost of Care in RA
06/20/2019
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar Computational Health Sciences Institute at the University of California, explains how artificial intelligence (AI) impacts the cost of care for patients with complex diseases, including rheumatoid arthritis, and...
Beau Norgeot, MS, of Bakar...
06/20/2019
First Report Managed Care
Interview
High Out-of-Pocket Costs Increase Medication Nonadherence Among Patients With RA
06/06/2019
Julie Gould
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at Monash University, explains why it is recommended that health policy makers globally identify an appropriate out-of-pocket amount to ensure costs do not affect medication adherence among patients with...
Parvaneh Heidari, PhD student at...
06/06/2019
First Report Managed Care
Interview
Techniques Used to Lessen Opioid Use, Address Rheumatologic Pain
05/09/2019
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending anesthesiologist and interventional pain management specialist at Northshore University Health System, explains how neuromodulation can help lessen pain caused by rheumatologic conditions as well as reduce opioid...
Nirav N Shah, MD, attending...
05/09/2019
First Report Managed Care
Interview
Why Higher Levels of Physical Activity Are Important in Preventing Chronic Diseases
04/11/2019
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD, rheumatologist and population scientist, discusses the importance of high levels of physical activity and explains why he suspects physical activity has beneficial effects on the immune system and also lowers systemic...
Jeffrey Sparks, MD,...
04/11/2019
First Report Managed Care
Interview
Assessing the Safety of a Treatment With A Label Warning for Patients With RA, COPD
04/08/2019
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of Epidemiology, Biostatistics and Medicine at McGill University in Montreal, discusses a label warning on a rheumatoid arthritis (RA) drug for patients with RA and COPD and he explains that the choice of biologic...
Samy Suissa, PhD, professor of...
04/08/2019
First Report Managed Care
Interview
Exploring the Cost Benefits of Cloud-Enabled Testing for RA Diagnosis
03/14/2019
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research economist at Precision Health Economics, discusses how rapid, cloud-enabled, onsite lab testing for RA diagnosis is valuable to payers and can potentially lower the number of visits per patient.
Kata Bognar, PhD, research...
03/14/2019
First Report Managed Care
Interview
Improving Access to Care, Outcomes Through Telemedicine for Patients With RA
03/06/2019
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate professor and clinical service chief of the division of rheumatology at Michigan Medicine in Ann Arbor, Michigan, discusses telemedicine in a rheumatology setting and explains how telemedicine will impact...
Wendy Marder, MD, associate...
03/06/2019
First Report Managed Care
Headshots
Interview
Leveraging Pharmacy-Led Population Health to Improve Outcomes and Reduce Costs
09/22/2025
Dovena Lazaridis, PharmD
In this interview, Dovena Lazaridis, PharmD, shares insights on building scalable pharmacy models that extend beyond dispensing, highlighting how population health frameworks and real-time data integration are transforming value-based care.
In this interview, Dovena Lazaridis, PharmD, shares insights on building scalable pharmacy models that extend beyond dispensing, highlighting how population health frameworks and real-time data integration are transforming value-based care.
In this interview, Dovena...
09/22/2025
First Report Managed Care
Lennartz
Videos
Reversing Pharmacy Deserts: A Call for Equitable Reimbursement in Underserved Markets
09/11/2025
Crystal Lennartz
Crystal Lennartz highlights how independent pharmacies are combating pharmacy deserts through fair reimbursement, digital innovation, and expanded clinical services—solidifying pharmacists’ role as essential, accessible providers in their...
Crystal Lennartz highlights how independent pharmacies are combating pharmacy deserts through fair reimbursement, digital innovation, and expanded clinical services—solidifying pharmacists’ role as essential, accessible providers in their...
Crystal Lennartz highlights how...
09/11/2025
First Report Managed Care
Interview
Invisible Technology and AI: The Future of Scaling Virtual Care
08/27/2025
Kent Dicks
Kent Dicks, CEO of Life365, shares how artificial intelligence (AI), “invisible technology,” and smarter reimbursement models can overcome barriers to virtual care and remote patient monitoring, transforming health care into a more proactive,...
Kent Dicks, CEO of Life365, shares how artificial intelligence (AI), “invisible technology,” and smarter reimbursement models can overcome barriers to virtual care and remote patient monitoring, transforming health care into a more proactive,...
Kent Dicks, CEO of Life365,...
08/27/2025
First Report Managed Care
Interview
From Promise to Practice: Evaluating the Impact of the Prior Authorization Reform Pledge
08/21/2025
Gordon Jaye
With more than 50 payers committing to faster, more transparent prior authorization processes, Gordon Jaye, executive director, RCM policy and industry engagement at EnableComp explores what the pledge could mean for turnaround times,...
With more than 50 payers committing to faster, more transparent prior authorization processes, Gordon Jaye, executive director, RCM policy and industry engagement at EnableComp explores what the pledge could mean for turnaround times,...
With more than 50 payers...
08/21/2025
First Report Managed Care
Interview
The Future of Medicaid: Standardized Data, Equitable Care, and AI-Powered Access
08/18/2025
Ryan Bullock
A health care executive from Aeroflow Health discusses how the Centers for Medicare & Medicaid Services (CMS)–driven push for interoperability standards, real-time patient data integration, expanded telehealth access, and the use of...
A health care executive from Aeroflow Health discusses how the Centers for Medicare & Medicaid Services (CMS)–driven push for interoperability standards, real-time patient data integration, expanded telehealth access, and the use of...
A health care executive from...
08/18/2025
First Report Managed Care
Headshots
Interview
Smarter Prior Authorization: Using AI to Improve Care Access and Cut Costs
08/11/2025
Brian Covino, MD; Siva Namasivayam
In this interview, Brian Covino, MD, and Siva Namasivayam of Cohere Health discuss how AI is revolutionizing the prior authorization process by dramatically improving speed, reducing administrative burden, and enhancing care accuracy—while...
In this interview, Brian Covino, MD, and Siva Namasivayam of Cohere Health discuss how AI is revolutionizing the prior authorization process by dramatically improving speed, reducing administrative burden, and enhancing care accuracy—while...
In this interview, Brian Covino,...
08/11/2025
First Report Managed Care
Hsu Headshot
Videos
Understanding the Changing Landscape of NSCLC in the US
07/11/2025
Melinda Hsu, MD
Dr. Melinda Hsu, thoracic oncologist and cancer survivorship director at UH Simon Cancer Center, shares insights on the evolving landscape of non–small cell lung cancer—highlighting challenges in early detection, treatment tolerability, and...
Dr. Melinda Hsu, thoracic oncologist and cancer survivorship director at UH Simon Cancer Center, shares insights on the evolving landscape of non–small cell lung cancer—highlighting challenges in early detection, treatment tolerability, and...
Dr. Melinda Hsu, thoracic...
07/11/2025
First Report Managed Care
Rodriguez Headshot
Videos
Addressing Disparities in NSCLC With Timely Biomarker Testing and Navigation Tools
07/11/2025
Estelamari Rodriguez, MD, MPH
Dr. Estelamari Rodriguez, clinical research lead for thoracic oncology at the University of Miami Sylvester Cancer Center, explores how early biomarker testing, equitable access, artificial intelligence (AI)-driven data integration, and...
Dr. Estelamari Rodriguez, clinical research lead for thoracic oncology at the University of Miami Sylvester Cancer Center, explores how early biomarker testing, equitable access, artificial intelligence (AI)-driven data integration, and...
Dr. Estelamari Rodriguez,...
07/11/2025
First Report Managed Care
Thawani
Videos
Advancing NSCLC Care: Targeted Strategies, Real-World Barriers, and the Future of Treatment Pathways
07/11/2025
Rajat Thawani, MD
Dr. Rajat Thawani, a thoracic oncologist at OHSU Knight Cancer Institute, discusses groundbreaking advances in lung cancer treatment—highlighting the promise of antibody-drug conjugates (ADCs), the critical role of biomarker testing, and the...
Dr. Rajat Thawani, a thoracic oncologist at OHSU Knight Cancer Institute, discusses groundbreaking advances in lung cancer treatment—highlighting the promise of antibody-drug conjugates (ADCs), the critical role of biomarker testing, and the...
Dr. Rajat Thawani, a thoracic...
07/11/2025
First Report Managed Care
Seema Bhat
Interview
Fixed vs Continuous CLL Treatment: Clinical and Economic Perspectives
07/08/2025
Seema A. Bhat, MD
Seema A. Bhat, MD, a physician at The Ohio State University and a member of both the chronic lymphocytic leukemia (CLL) and hairy cell leukemia treatment groups, shared her expertise with First Report Managed Care on the evolving landscape of...
Seema A. Bhat, MD, a physician at The Ohio State University and a member of both the chronic lymphocytic leukemia (CLL) and hairy cell leukemia treatment groups, shared her expertise with First Report Managed Care on the evolving landscape of...
Seema A. Bhat, MD, a physician...
07/08/2025
First Report Managed Care
FRMC Volume 22, Issue 3

Current Issue

September 2025
Volume 22
Issue 3
Current Issue
Issue Archive

Recent Stories

News
Study Highlights Motivators and Barriers to Clinical Trial Enrollment in Rheumatoid Arthritis
05/07/2025
Grace Taylor, MS, MA
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what motivates patients with rheumatoid arthritis to participate in clinical trials.
New findings reveal what...
05/07/2025
First Report Managed Care
News
Patients With Rheumatoid Arthritis Experience Substantial Economic and Quality-of-Life Burden
04/08/2025
Grace Taylor, MS, MA
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data, researchers found that rheumatoid arthritis imposes a substantial economic and humanistic burden, driven largely by prescription costs and impaired daily functioning.
Using national survey data,...
04/08/2025
First Report Managed Care
News
Adverse Events Common With Glucocorticoids for Polymyalgia Rheumatica
04/17/2024
Jolynn Tumolo
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid treatment reduced inflammatory parameters in real-world patients with polymyalgia rheumatica (PMR), more than a third still showed above-normal levels throughout a 52-week follow-up period, according to study results...
Although glucocorticoid...
04/17/2024
First Report Managed Care
News
Identifying Large-Vessel Vasculitis in Polymyalgia Rheumatica: Key Clinical and Laboratory Red Flags
04/05/2024
Lisa Kuhns, PhD, MD
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for large-vessel vasculitis in isolated polymyalgia rheumatica (PMR) include inflammatory back pain, significant pelvic involvement, widespread lower extremity pain, marked inflammatory response indicated by specific lab...
Potential red flags for...
04/05/2024
First Report Managed Care
News
Potential for Target-To-Treat Strategies for Polymyalgia Rheumatica and Giant Cell Arthritis
03/28/2024

Emry Lloyd

Emry Lloyd
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat strategies for polymyalgia rheumatica and giant cell arthritis and how physicians can understand these strategies to suitably treat patients were revealed in a literature review.
Different target-to-treat...
03/28/2024
First Report Managed Care

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2025 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use